Printer Friendly

UNIGENE LABORATORIES EXTENDS CLASS B WARRANT EXPIRATION DATE

 UNIGENE LABORATORIES EXTENDS CLASS B WARRANT EXPIRATION DATE
 FAIRFIELD, N.J., May 13 /PRNewswire/ -- Unigene Laboratories, Inc.


(NASDAQ: UGNE), today announced that it is extending the expiration date of its Class B warrants (NASDAQ: UGNEZ) by one year to Aug. 11, 1993. The Class B warrants are currently exercisable at $5.00 for one share of common stock.
 "Unigene is in excellent financial condition and we are very encouraged regarding the progress of our internal programs and optimistic about the prospects for developing strategic relationships involving our major technologies. However, the well documented recent trend towards lower share prices throughout the pharmaceutical and biotechnology industries has created undue pressure on many of our investors," stated Warren P. Levy, president of Unigene. "We therefore feel that, at this time, it is in the best interests of both our common stockholders and our warrantholders for us to extend the expiration date of the Class B warrants."
 Unigene Laboratories, Inc., has developed a proprietary amidation process capable of producing peptide hormones for the treatment of a variety of diseases and disorders including osteoporosis, diabetes and hypertension.
 -0- 5/13/92
 /CONTACT: William Steinhauer of Unigene Laboratories, 201-882-0860/
 (UGNE) CO: Unigene Laboratories, Inc. ST: New Jersey IN: MTC SU:


GK-LR -- NY002 -- 9458 05/13/92 08:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 13, 1992
Words:214
Previous Article:CAMPBELL REPORTS ANOTHER QUARTER OF RECORD EARNINGS
Next Article:A. L. LABORATORIES REPORTS FIRST QUARTER EARNINGS
Topics:


Related Articles
CORTEX EXTENDS CLASS A, CLASS B AND CLASS C WARRANTS
UNIGENE LABORATORIES EXTENDS CLASS B WARRANT EXPIRATION DATE
DALTEX MEDICAL SCIENCES, INC. EXTENDS THE EXPIRATION DATES OF ITS CLASS A AND CLASS B WARRANTS
UNIGENE RECEIVES AUTHORIZATION TO CONDUCT PHASE III CLINICAL TRIAL FOR OSTEOPOROSIS PRODUCT REGISTRATION IN EUROPE
UNIGENE'S OSTEOPOROSIS PILL EXCEEDS PERFORMANCE Target In All Subjects In Latest Phase 1 Clinical Trial
UNIGENE LABORATORIES ANNOUNCES CLASS B WARRANT ADJUSTMENT
Unigene Laboratories Extends Class B Warrant Expiration Date
Unigene's Osteoporosis Pill Exceeds Performance Target in All Subjects in Latest Phase 1 Clinical Trial
Unigene and Warner-Lambert Execute Letter of Intent to Develop Oral Calcitonin for Osteoporosis
Unigene Receives Notice of Allowance for Key U.S. Patent for Oral Delivery of Calcitonin for Osteoporosis Treatment

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters